Comparative Pharmacology
Head-to-head clinical analysis: CANAGLIFLOZIN versus DAPZURA RT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANAGLIFLOZIN versus DAPZURA RT.
CANAGLIFLOZIN vs DAPZURA RT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Selective estrogen receptor degrader (SERD) and antagonist; binds to estrogen receptor alpha (ERα), induces its degradation, and inhibits estrogen-dependent growth.
100 mg orally once daily; may increase to 300 mg once daily for additional glycemic control.
20 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 10.6–13.1 hours (single dose); steady-state: ~12.9 hours. Clinically, supports once-daily dosing with sustained SGLT2 inhibition over 24 hours.
Clinical Note
moderateCanagliflozin + Gatifloxacin
"Canagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateCanagliflozin + Rosoxacin
"Canagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateCanagliflozin + Levofloxacin
"Canagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateCanagliflozin + Trovafloxacin
"Canagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life: 12-15 hours (sufficient for once-daily dosing in most patients; prolonged in renal impairment).
Renal: 33% (primarily tubular secretion, ~1% unchanged in urine; remainder as glucuronide metabolites); Fecal: 52% (as parent drug and metabolites); Biliary: minor (enterohepatic circulation suspected but not quantified).
Primarily renal: 70-80% unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor